MSD Partners’s Intellia Therapeutics NTLA Stock Holding History

MSD Partners’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-30,000	Closed	-$577K	–	35
2017 Q4	$577K	Buy	+30,000	New	+$693K	0.03%	19

Other funds holding NTLA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

MSD Partners's NTLA Position: Q1 2018 in Review

MSD Partners sold out of Intellia Therapeutics (NTLA) in Q1 2018, closing a stake of 30,000 shares — an estimated $577K sold.

MSD Partners first reported a position in NTLA in Q4 2017 and held it in 1 quarter. The position peaked at $577K in Q4 2017. 130 funds tracked by Wall St. Rank hold NTLA as of Q1 2018.

MSD Partners reported no remaining Intellia Therapeutics position as of Q1 2018 after selling out during the quarter.
MSD Partners sold 30,000 Intellia Therapeutics shares in Q1 2018, an estimated $577K.
MSD Partners first reported a position in Intellia Therapeutics in Q4 2017 and held it in 1 quarter.
MSD Partners's Intellia Therapeutics position peaked at $577K in Q4 2017.
130 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2018.

Based on MSD Partners's 13F filing for Q1 2018, filed 15 May 2018.